A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
This study has been terminated.
Information provided by (Responsible Party):
First received: September 12, 2006
Last updated: January 31, 2012
Last verified: January 2012
This study will evaluate the safety and efficacy of a new allergy medication
Intervention Model: Parallel Assignment
|Ages Eligible for Study:
||6 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Be at least 6 years of age, of any race, or either gender.
- Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.
- Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.
- Positive bilateral CAC reaction at Visit 1 & 2.
- Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.
- Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
- Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit
No Contacts or Locations Provided
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 12, 2006
||January 31, 2012
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 10, 2013
Immune System Diseases
Histamine H1 Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs